All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @morethanmuscle.nicholas on TikTok · 44s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @morethanmuscle.nicholas's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Anovar and testosterone update week one. Yes, the pumps are great. Yes, the strength improvement is
  2. 0:06great. Yes, the vascularity is notable. But the real change that's happened has been the psychological
  3. 0:14factors of anovar. So anovar will attach to your androgen receptors in the central nervous system,
  4. 0:20which will boost your dopamine. So I feel so laser focused and dialed in especially during my
  5. 0:28workouts. It's made a huge difference. Like I just want to push harder. I just want to do another
  6. 0:33rep another set every time. I actually I honestly I can't wait for the day to be over so that I can
  7. 0:38wake up and go to the gym again tomorrow because it just simply it just feels good.

TRT and Anavar stacking: what the side effects data really shows

MTM

TikTok creator

132.2K viewsWatch on TikTok

Quick answer

The creator is self-reporting week one of an oxandrolone and testosterone stack, framing the psychological effects as the underreported story. Oxandrolone binds CNS androgen receptors and preclinical data supports dopaminergic involvement in AAS-related mood changes, but human mechanistic evidence is limited and week-one psychological effects may partly reflect testosterone optimization rather than oxandrolone specifically. The motivational intensity described is consistent with documented AAS effects on reward pathways and should be recognized as a potential early marker of dependence risk, not simply a benefit.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For TRT and Anavar stacking: what the side effects data really shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

TRT and Anavar stacking: what the side effects data really shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "TRT and Anavar stacking: what the side effects data really shows" from MTM. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is self-reporting week one of an oxandrolone and testosterone stack, framing the psychological effects as the underreported story.

The reason this review is not generic is the source wording and the canonical claim label "trt cycle update part 2 the effects most people leave out moreth." In this clip, the useful excerpt is: "Anovar and testosterone update week one." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Kanayama et al.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is self-reporting week one of an oxandrolone and testosterone stack, framing the psychological effects as the underreported story.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is self-reporting week one of an oxandrolone and testosterone stack, framing the psychological effects as the underreported story. Oxandrolone binds CNS androgen receptors and preclinical data supports dopaminergic involvement in AAS-related mood changes, but human mechanistic evidence is limited and week-one psychological effects may partly reflect testosterone optimization rather than oxandrolone specifically. The motivational intensity described is consistent with documented AAS effects on reward pathways and should be recognized as a potential early marker of dependence risk, not simply a benefit.
  • Oxandrolone does bind CNS androgen receptors, including in dopamine-rich reward regions like the nucleus accumbens, but the direct 'dopamine boost' claim is a simplification of poorly characterized human neuropharmacology.
  • Kanayama et al. (2009, Annals of Clinical Psychiatry) estimated approximately 30% of long-term AAS users develop dependence, driven by the same CNS mechanisms described as benefits in this video.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Oxandrolone does bind CNS androgen receptors, including in dopamine-rich reward regions like the nucleus accumbens, but the direct 'dopamine boost' claim is a simplification of poorly characterized human neuropharmacology.
  • Kanayama et al. (2009, Annals of Clinical Psychiatry) estimated approximately 30% of long-term AAS users develop dependence, driven by the same CNS mechanisms described as benefits in this video.
  • Pope and Katz (1994, Biological Psychiatry) documented hypomanic mood elevation in controlled AAS trials, validating that the psychological intensity described is real, not placebo, but also not purely positive.
  • Week-one psychological effects during a testosterone plus oxandrolone stack cannot reliably be attributed to anavar alone, as testosterone optimization independently produces measurable mood and motivation improvements.
  • Oxandrolone is a Schedule III controlled substance with legitimate clinical indications including muscle wasting and burn recovery, but its use as a performance-enhancing stack is a distinct category with a different risk-benefit profile.
  • AAS CNS effects involve multiple neurotransmitter systems including serotonin, GABA, and endogenous opioids, not only dopamine, making single-neurotransmitter explanations an oversimplification of current research.
  • The motivational state described, training anticipation so strong it dominates the end of the day, is consistent with incentive salience, a reward-system phenomenon associated with compulsive behavior and dependence risk.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @morethanmuscle.nicholas actually say?

In week one of a self-reported anavar and testosterone cycle, the creator claims the most notable change isn't physical. "The real change that's happened has been the psychological factors of anovar," he says, describing laser focus, gym motivation so strong he can't wait for tomorrow, and a general feeling that things "just feels good." He attributes this directly to a mechanism: anavar "attach[es] to your androgen receptors in the central nervous system, which will boost your dopamine." That's a specific pharmacological claim, not just a vibe report, and it deserves scrutiny.

To his credit, he does acknowledge the physical effects, pumps, strength, vascularity, but he explicitly frames the psychological shift as the underreported story. That framing is actually more interesting than the usual before-and-after content. Whether the mechanism he cites holds up is a different question.

Does the science back this up?

Partly, but the dopamine claim is being stated with more confidence than the evidence warrants. Oxandrolone (the generic name for anavar) does bind androgen receptors, including those expressed in the central nervous system. That part is real. But the direct leap from "CNS androgen receptor binding" to "boosted dopamine" oversimplifies a genuinely complex picture.

Androgen receptors in the brain are expressed in regions like the hypothalamus, amygdala, and nucleus accumbens, which is a dopamine-rich reward circuit area. Research by Wood (2004, Neuroscience and Biobehavioral Reviews) showed anabolic-androgenic steroids can influence dopaminergic tone in rodent models, particularly in reward pathways. However, human data is sparse and confounded. A review by Kanayama et al. (2008, Drug and Alcohol Dependence) noted that AAS use is associated with mood and motivational changes, but isolating a clean dopamine mechanism in humans remains difficult. The felt sense of motivation and reward he describes is real and documented. Calling it a dopamine boost caused by CNS androgen receptor activation is a plausible hypothesis, not a confirmed mechanism.

What did they get wrong (or right)?

He got the broad strokes right and the specific mechanism oversold. Oxandrolone does have meaningful CNS activity. The motivational and mood-enhancing effects of anabolic steroids are documented in clinical and preclinical literature. Feeling "laser focused" and motivated during an oxandrolone cycle is not unusual and is biologically plausible, not placebo.

What he gets wrong is the certainty. Saying anavar "will boost your dopamine" states as settled fact something researchers are still working out. The CNS effects of AAS involve serotonin, GABA, and opioid systems too, not just dopamine. Pope and Katz (1994, Biological Psychiatry) documented hypomanic and mood-elevating effects in controlled AAS trials, but the neurotransmitter specifics remain contested. There's also a week-one problem: baseline testosterone optimization from TRT alone can produce significant mood and motivation improvements. Attributing the psychological lift specifically to anavar, and specifically to dopamine, at week one is doing a lot of causal work with limited personal data. He also doesn't mention that these same CNS androgen receptor effects are part of why AAS carry documented addiction and dependence risk, which is a significant omission for a platform presenting this as a straightforward cycle update.

What should you actually know?

If you're considering or already using anabolic steroids, the psychological effects are not a side note. They are pharmacologically real and carry real risk. The motivational intensity the creator describes, wanting to push harder, "can't wait for the day to be over" to train again, maps onto what addiction researchers call incentive salience, the reward system driving compulsive behavior. Kanayama et al. (2009, Annals of Clinical Psychiatry) estimated that roughly 30% of long-term AAS users develop dependence. The same CNS receptor activity that makes you feel dialed in is the mechanism that can make stopping feel unbearable.

Oxandrolone is a Schedule III controlled substance in the US. It has legitimate medical uses, including treatment of muscle wasting in HIV patients and recovery from severe burns, at doses and durations supervised by physicians. The cycle being described here is bodybuilding use, not TRT in any clinical sense. TRT refers to hormone replacement to restore physiological testosterone levels. Stacking it with oxandrolone for performance is a different category of use with a different risk profile. Anyone experiencing significant mood changes, motivation spikes, or psychological intensity on any AAS should flag that to a physician, not just document it on TikTok.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

MTM · TikTok creator

132.2K views on this video

Cycle update part 2. The effects most people leave out. #morethanmuscle #TRT #anavar #menshealth #fitnesstruth

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about oxandrolone does bind cns?

Oxandrolone does bind CNS androgen receptors, including in dopamine-rich reward regions like the nucleus accumbens, but the direct 'dopamine boost' claim is a simplification of poorly characterized human neuropharmacology.

What does the video say about kanayama et al. (2009, annals of clinical psychiatry) estimated approximately?

Kanayama et al. (2009, Annals of Clinical Psychiatry) estimated approximately 30% of long-term AAS users develop dependence, driven by the same CNS mechanisms described as benefits in this video.

What does the video say about pope?

Pope and Katz (1994, Biological Psychiatry) documented hypomanic mood elevation in controlled AAS trials, validating that the psychological intensity described is real, not placebo, but also not purely positive.

What does the video say about week-one psychological effects during a testosterone plus oxandrolone stack cannot?

Week-one psychological effects during a testosterone plus oxandrolone stack cannot reliably be attributed to anavar alone, as testosterone optimization independently produces measurable mood and motivation improvements.

What does the video say about oxandrolone?

Oxandrolone is a Schedule III controlled substance with legitimate clinical indications including muscle wasting and burn recovery, but its use as a performance-enhancing stack is a distinct category with a different risk-benefit profile.

What does the video say about aas cns effects involve multiple neurotransmitter systems including serotonin, gaba,?

AAS CNS effects involve multiple neurotransmitter systems including serotonin, GABA, and endogenous opioids, not only dopamine, making single-neurotransmitter explanations an oversimplification of current research.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by MTM, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.